Jinxin Reproductive's four major H2 indicators fully rebound after 25 years; net profit after adjustments in the second half of the year increased by 54.9% quarter-on-quarter

Integrated Assisted Reproduction Service Provider JinXin Reproductive (1951.HK) released its 2025 financial report on March 26. The report shows that in 2025, the operating revenue was 2.649 billion yuan, with 28,039 egg retrieval cycles. According to Sullivan’s “China Assisted Reproduction Industry Development White Paper 2026,” based on the number of egg retrieval cycles, JinXin Reproductive has become China’s largest IVF medical service provider. Its Sichuan JinXin Xinan Women and Children’s Hospital ranks first in the western region, and Shenzhen Zhongshan Maternity Hospital is among the top tier in Shenzhen, Hong Kong, and Macau.

It is worth noting that JinXin Reproductive’s performance in the first and second halves of 2025 showed a “mixed picture.” Based on the four key indicators—“egg retrieval cycles,” “management revenue,” “adjusted EBITDA,” and “adjusted net profit”—the second half of 2025 experienced a full rebound, with significant quarter-over-quarter growth.

According to the financial data, in the second half of the year, egg retrieval cycles increased by 3.1%, management revenue grew by 3.8%, adjusted EBITDA rose by 18.2%, and adjusted net profit surged by 54.9%. Multiple institutions analyze that the decline in performance in the first half was mainly due to overseas goodwill asset impairments. The substantial improvement in the second half indicates that the company’s operational fundamentals and market recognition are stable.